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ABSTRACT
Adverse events related to long-term use of bisphosphonates have raised interest in temporary drug discontinuation. Trends in
bisphosphonate discontinuation and restart, as well factors associated with these decisions, are not fully understood at a population
level. We investigated temporal trends of bisphosphonate discontinuation from 2010 to 2015 and identified factors associated with
discontinuation and restart of osteoporosis therapy. Our cohort consisted of long-term bisphosphonate users identified from 2010 to
2015 Medicare data. We defined discontinuation as ≥12 months without bisphosphonate prescription claims. We used conditional
logistic regression to compare factors associated with alendronate discontinuation or osteoporosis therapy restart in the 120-day
period preceding discontinuation or restart referent to the 120-day preceding control periods. Among 73,800 long-term bisphospho-
nate users, 59,251 (80.3%) used alendronate, 6806 (9.2%) risedronate, and 7743 (10.5%) zoledronic acid, exclusively. Overall, 26,281
(35.6%) discontinued bisphosphonates for at least 12 months. Discontinuation of bisphosphonates increased from 1.7% in 2010,
reaching a peak of 14% in 2012 with levels plateauing through 2015. The factors most strongly associated with discontinuation of
alendronate were: benzodiazepine prescription (adjusted odds ratio [aOR] = 2.5; 95% confidence interval [CI] 2.1, 3.0), having a
dual-energy X-ray absorptiometry (DXA) scan (aOR = 1.8; 95% CI 1.7, 2.0), and skilled nursing facility care utilization (aOR = 1.8;
95% CI 1.6, 2.1). The factors most strongly associated with restart of osteoporosis therapy were: having a DXA scan (aOR = 9.9;
95% CI 7.7, 12.6), sustaining a fragility fracture (aOR = 2.8; 95% CI 1.8, 4.5), and an osteoporosis or osteopenia diagnosis (aOR = 2.5;
95% CI 2.0, 3.1). Our national evaluation of bisphosphonate discontinuation showed that an increasing proportion of patients on
long-term bisphosphonate therapy discontinue medications. The factors associated with discontinuation of alendronate were pri-
marily related to worsening of overall health status, whereas traditional factors associated with worsening bone health were associ-
ated with restarting osteoporosis medication. © 2019 American Society for Bone and Mineral Research.
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Introduction
Bisphosphonates are widely prescribed for the treatment ofosteoporosis, of which alendronate is the most commonly
prescribed.(1) Given their high skeletal retention, prolonged sup-
pression of bone remodeling continues to occur after discontin-
uation.(2) This unique feature of bisphosphonates, including
alendronate, is likely the main mechanism that mediates the
observed sustained lumbar spine bone mineral density (BMD)
found in the alendronate withdrawal arm of the Fracture Inter-
vention Trial Long-term Extension (FLEX) clinical trial.(3)
Over the last decade, there has been a significant decline in
the use of bisphosphonates.(1,4) This decline is related, in part,
to the fear of rare adverse events, namely osteonecrosis of the
jaw (ONJ) and atypical femoral fractures. These possible side
effects were highlighted by US Food and Drug Administration
(FDA) announcements in 2005 and 2007, respectively.(5) In addi-
tion, atypical femoral fractures may be related to the prolonged
antiresorptive effects of bisphosphonates,(6) although there is
less compelling evidence that ONJ is duration dependent. In
2016, a Task Force of the American Society for Bone and Mineral
Research (ASBMR) advocated a “drug holiday” after 5 years of
continuous bisphosphonate therapy.(7) More than 80% of US
physicians consider a drug holiday after long-term bisphospho-
nate treatment.(8) Retrospective analyses and a systematic
review showed that a drug holiday of 12 months in patients with
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2 years or more of previous bisphosphonate exposure might be
safely executed without a subsequent increase in fractures.(9–11)
In contrast, bisphosphonate discontinuation of more than
3 years has been associated with an increased rate of hip frac-
tures.(12) However, the appropriate timing and duration of a drug
holiday for each patient remains controversial.
Although the effects of bisphosphonates are long-lasting and a
prolonged drug holiday may be warranted in some patients, oste-
oporosis is a chronic condition and resumption of an osteoporosis
therapy is likely to be necessary for most people. The optimal
duration of a bisphosphonate drug holiday may likely be influ-
enced by a number of variables, including baseline fracture risk,
as well as changes in BMD and bone turnover markers (BTMs),
fractures, altered risk factors, or changes in comorbidities that
occur during the holiday.(7,13) However, the patient and provider
factors associated with the suspension of bisphosphonates and
restart of osteoporosis medications are not fully known at a
population-level and might vary based on a number of factors
including route of administration (ie, intravenous versus oral
bisphosphonates) or drug affinity to bone. A previous analysis of
Medicare data from 2006 to 2010 reported that baseline charac-
teristics of patients (sex, race, income, number of visits) at the time
of bisphosphonate treatment initiation were only weakly associ-
atedwith subsequent discontinuation.(14) Theseweak associations
may be explained by the presence of more relevant events, closer
to the time of discontinuation, which presumably could have pre-
cipitated the decision to stop therapy. Indeed, circumstances
occurring at follow-up time points (eg, results of a dual-energy
X-ray absorptiometry [DXA], high drug co-pays, or experiencing
adverse events) were more predictive of medication adherence
than factors measured at therapy initiation in one study.(14)
Previous analyses included patients who discontinued osteo-
porosis medication for a short period (90 days), which may not
truly represent an intentional drug discontinuation. To our
knowledge, past studies also have not investigated reasons asso-
ciated with the restart of osteoporosis therapy. Thus, a better
understanding of patient and provider variables immediately
preceding bisphosphonate long-term discontinuation and
restart is needed to guide osteoporosis treatment strategies
and management with a personalized medicine approach.
Although retrospective cohort designs can comprehensively
assess the reasons for discontinuation/restart of therapy, they
lack the ability to control personal characteristics that can con-
found these associations. In contrast, a case-crossover is a time-
focused design in which each case serves as its own control
across different time periods, allowing for a unique analytical
approach to investigate factors thatmay precipitate bisphospho-
nate discontinuation and subsequent restarting therapy, thereby
providing better control for temporally associated confounding
than other study designs.(15) The aims of the present study were
to: 1) describe the temporal trends of bisphosphonate discontin-
uation among women in a national Medicare population, and 2)
evaluate patient and provider factors associated with discontin-
uation of alendronate and restart of any osteoporosis medication
using a case-crossover design study.
Materials and Methods
Study design overview
To describe the temporal trends of bisphosphonate discontinua-
tion from 2010 to 2015 (January 1, 2010 to December 31, 2014),
we created a retrospective cohort derived from all women with
fee-for-serviceMedicare coverage receiving any bisphosphonate
therapy from 2006 to 2012. Data derived from the Chronic Dis-
ease Warehouse included information on demographics; insur-
ance coverage; claims for inpatient, outpatient, skilled nursing
facility, noninstitutional provider, home health, hospice, durable
medical equipment services; and claims for prescription drugs.
We identified long-term adherent bisphosphonate women users
based on proportion of days covered (PDC)(16) ≥80% for at least
3 continuous years who then were at risk to subsequently stop
therapy. The PDC considers the days that are covered by a pre-
scription and represents a measure of drug adherence based
on prescription pharmacy claims. A PDC of 80% reflects a patient
likely taking their medication most of the time. This threshold of
PDC has been shown to be sufficient to achieve the potential
clinical benefit of oral bisphosphonates(17) for fracture risk reduc-
tion.(18) We restricted our analyses to only highly adherent
patients in the first 3 years of treatment to mirror the pattern
of drug utilization typical for patients in the pivotal osteoporosis
clinical trials and to focus on those patients who might have pre-
planned and/or physician-advised drug discontinuation given
that duration of exposure with good adherence.(17)
We analyzed temporal trends of bisphosphonate discontinua-
tion according to calendar time in 6-month intervals starting
January 1, 2010 through December 31, 2014. To identify time-
varying factors associated with discontinuation of alendronate
and restart of that or any other osteoporosis therapy, we con-
ducted a case-crossover analysis. All study procedures were
approved by the institutional review board of the University of
Alabama at Birmingham.
Bisphosphonate discontinuation temporal trend analysis
We conducted a retrospective analysis on temporal trends of drug
discontinuation in the US using national Medicare data from 2010
to 2015. Eligible subjects for the cohort included women
≥65 years, with fee-for-service Medicare beneficiaries, who lived
in the US and who were prescribed any bisphosphonate(s) for at
least 3 years with high adherence based on the proportion of days
covered (PDC).(16) PDC was measured from the time of first BP use
and was estimated beginning at day 1096 (3 years) after BP initia-
tion. We defined start of follow-up (index date) as the first day on
or after day 1096 that PDC exceeded 80%.
The definition of discontinuation was subsequent cessation of
bisphosphonates for a period of ≥12 months. We restricted the
analysis to alendronate, risedronate, and zoledronic acid users. A
priori, we excluded ibandronate because of the small amount of
ibandronate users for both oral and intravenous routes of admin-
istration.We requiredwomen in the cohort to have no evidence of
malignancy (diagnosis codes or treatment and ignoring nonmela-
noma skin cancer), diagnosis of Paget’s disease, or osteogenesis
imperfecta during all available baseline data (from first eligible
coverage start date), and who did not have previous systemic hor-
mone therapy.Womenwere excluded if they had prescriptions for
other osteoporosis drugs (eg, raloxifene, teriparatide, calcitonin, or
denosumab) or use of bisphosphonates not approved in US for
treatment of osteoporosis (eg, tiludronate, pamidronate, and eti-
dronate) in the 365 days before the index date.
Case-crossover design
We restricted our case-crossover study design to women who
took alendronate, the most frequently prescribed oral bispho-
sphonate in the US and internationally, in order to increase the
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homogeneity of the analysis.(1) Indeed, the factors that contrib-
ute to drug discontinuations might be different for zoledronic
acid (which is characterized by intravenous administration) and
risedronate (a less potent bisphosphonate than alendronate).
In this design, every patient contributed one hazard period and
two control periods to each outcome (restart and/or discontinu-
ation). The case-crossover design schema is depicted in Fig. 1.
We assessed factors measured during the 120-day hazard period
before alendronate discontinuation and two consecutive control
periods of 120 days before discontinuation. The hazard period
was anchored at the time of alendronate discontinuation (day
−120 to 0) and the two consecutive control periods were sepa-
rated from the hazard period by a 120-day gap.
The approach for assessment of factors associated with the
restart of any osteoporosis medication was similar, only that
analysis was conducted on the subgroup of women that had pre-
viously discontinued alendronate. In the restart case-crossover
analysis, the time frame without any osteoporosis medication
before restarting had to be at least 480 days, to be consistent
with expectations regarding the minimum length of a drug hol-
iday. This design feature of the analysis thus allowed for four
120-day windows (two control periods, one gap period, and
one hazard period). We conducted sensitivity analysis widening
the hazard period from days −90 to +30. In this sensitivity analy-
sis, the gap was widened to 150 days and extended from day
−91 to day −240.
We used multivariable conditional logistic regression to com-
pare factors associated with alendronate discontinuation and
osteoporosis medication restart in the hazard period referent
to the preceding control periods. The factors included in themul-
tivariable analysis for both discontinuation cohort and restart
cohort were the following: diagnosis of osteoporosis or osteope-
nia, DXA, measurement of BTMs (osteocalcin, phosphatase alka-
line, serum procollagen type I N-terminal propeptide, serum
procollagen I carboxyterminal propeptide, serum or urine colla-
gen type I cross-linked N-terminal telopeptide A, serum or urine
hydroxyproline, serum or urine collagen type I cross-linked
C-terminal telopeptide, tartrate-resistant acid phosphatase),
case-qualifying fragility fracture, fall, at least one visit with an
osteoporosis specialist (rheumatology or endocrinology), num-
ber of unique days with at least one physician visit (categorized
based on distribution of the data [eg, tertiles]), any emergency
room visit, hospitalization due to stroke, myocardial infarction,
cardiovascular disease, or chronic heart disease (ICD 433.x1,
434.x1, 436; 410.x1), hospitalization for noncardiovascular
reason, number of hospitalization days (categorized based on
distribution of the data [eg, tertiles]), new diagnosis of Alzhei-
mer’s or other dementia, new diagnosis of depression or anxiety,
Charlson comorbidity index(19) and any skilled nursing facility
(SNF) care. We also included use of medications that affect frac-
ture risk as potential factors associated with discontinuation/
restart (alpha blockers, anticholinergic antihistamines, antipsy-
chotics, barbiturates, benzodiazepines, beta blockers, muscle
relaxants, nonbenzodiazepines or nonbenzodiazepine GABA
receptor agonists, opioids, oral glucocorticoids, proton pump
inhibitors, selective serotonin reuptake inhibitors, tricyclic anti-
depressants, vasodilators). We identified these medications
using the criterion of at least one claim for a prescription filled
in Medicare Part D data during the relevant time window. All sta-
tistical analyses were performed with SAS Version 9.3 (SAS Insti-
tute, Inc, Cary, NC, USA; Enterprise Guide v4.3).
Results
We identified 107,633 adherent long-term bisphosphonate users
(Fig. 2). We only included the 83,973 patients with prescriptions
for a single bisphosphonate (ever) and excluded those who
switched between bisphosphonate medications. The final
cohort was composed of 73,800 women, of which 59,251
(80.3%) used alendronate exclusively, 6806 (9.2%) used risedro-
nate exclusively, and 7743 (10.5%) used zoledronic acid exclu-
sively. The median (IQR) follow-up was 2.8 (1.5–4.1), 2.3
(1.1–4.0), and 2.2 (1.3–3.3) years, respectively.
Temporal trends of bisphosphonate discontinuation
Overall, 26,281 (35.6%) women discontinued their respective
bisphosphonate for at least 12 months. Long-term bisphospho-
nate users who underwent a drug discontinuation increased
from 1.7% in 2010, reaching a peak of 14.0% in 2012, and con-
tinuing in a relatively stable to slightly declining fashion thereaf-
ter (Fig. 3). Discontinuation frequency varied by bisphosphonate:
20,455 (34.5%) for alendronate users, 2388 (35.1%) for risedro-
nate users, and 3438 (44.4%) for zoledronic acid users, with a
median follow-up after bisphosphonate discontinuation (IQR)
of 1.4 (0.6–2.5), 1.6 (0.7–2.6), and 1.0 (0.4–1.8), respectively.
Among women who discontinued their drug for ≥12 months,
87.6% (23,041) did not restart osteoporosis therapy, whereas
12.3% (3240) restarted an osteoporosis therapy during follow-
up. Characteristics of the analyzed population are represented
Fig. 1. Case-crossover design for identifying factors associated with alendronate discontinuation and restart of osteoporosis medication (restart cohort is
a subgroup of the discontinuation cohort).
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in Table 1 (stratified by patients who underwent drug discontin-
uation versus those who did not) and Table 2 (stratified by
whether individuals eventually restarted any osteoporosis med-
ication versus those who did not). For themany factors that were
measured at baseline, we found no differences in the frequency
of drug discontinuation, race/ethnicity, previous DXA scans, glu-
cocorticoid use, or fragility fractures between those who stopped
versus those who restarted, nor between beneficiaries who used
different oral bisphosphonates (eg, alendronate 34.5% discon-
tinuation rate versus risedronate 35.1% discontinuation rate).
However, beneficiaries who used zoledronic acid were more
likely to discontinue the drug compared with oral bisphospho-
nate (zoledronic acid 44.4%). Furthermore, women who used
zoledronic acid were more likely to be white, be on glucocorti-
coids, and have had a previous DXA scan or a previous fragility
fracture compared with those on oral bisphosphonates. In addi-
tion, women who discontinued zoledronic acid were more likely
to restart the treatment compared with oral bisphosphonates
(zoledronic acid 21.4% versus alendronate 10.7% versus risedro-
nate 13.4%).
Time-varying factors associated with discontinuation/
restarting alendronate using case-crossover design
Among alendronate users, 20,455 (34.5%) discontinued for
≥12 months, serving as our sample for the case-crossover cohort
to identify factors associated with discontinuation. Multivariable
analysis demonstrated several factors associated with discontin-
uation, represented as adjusted odds ratio (aOR) (95% confi-
dence interval [CI]) (Table 3). The factors most strongly
associated with discontinuation included: a new prescription of
benzodiazepine (aOR = 3.1 [2.7–3.6]), Alzheimer’s or other
dementia diagnosis (aOR = 2.0 [1.8, 2.3]), SNF care utilization
(aOR = 1.9 [1.7, 2.2]), prescription of proton pump inhibitor
Fig. 2. Algorithm for selection of the eligible women in the final cohort. BP = bisphosphonate; OP = osteoporosis; PDC = proportion of days covered.
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(aOR = 1.8 [1.6, 1.9]), performing a DXA scan (aOR = 1.7 [1.7, 1.6]),
hospitalization (aOR = 1.5 [1.3, 1.6]), osteoporosis and osteopenia
diagnosis (aOR = 1.4 [1.3, 1.5] and aOR = 1.8 [1.7, 2.0], respec-
tively). Many medication prescriptions and greater use of medi-
cal services were also significantly related to discontinuation of
alendronate (Table 3).
Among women taking alendronate who underwent a drug
discontinuation, 2185 (10.7%) restarted any osteoporosis medi-
cation. Women who restarted an osteoporosis medication dur-
ing the follow-up served as the sample for the case-crossover
study for identifying factors associated with osteoporosis ther-
apy restart (Table 4). The factors most strongly associated with
osteoporosis treatment restart included: receiving a DXA scan
(aOR = 9.0 [7.6, 10.7]), sustaining a fragility fracture (aOR = 2.8
[1.9, 4.0]), benzodiazepine prescription (aOR = 2.7 [1.8, 3.9]),
new osteoporosis and osteopenia diagnosis (aOR = 2.3 [1.9, 2.8]
and aOR = 1.5 [1.1, 2.1] respectively), Alzheimer’s or other
dementia diagnosis (aOR = 2.0 [1.4, 2.9]), SNF care utilization
(aOR = 1.9 [1.3, 2.8]), at least one visit with an osteoporosis spe-
cialist (rheumatologist or endocrinologist) (OR = 1.4 [1.0, 1.9]),
and an opioid prescription (OR = 1.3 [1.1, 1.6]).
Discussion
Using a national cohort of long-term bisphosphonate users, we
describe temporal trends and factors associated with bispho-
sphonate discontinuations and subsequent restart of osteoporo-
sis medications. From 2010 to 2015, slightly more than one-third
of the women in Medicare with long-term bisphosphonate treat-
ment discontinued treatment for 12 months or more. We found
that there was an increase in bisphosphonate discontinuation
from just under 2% in the first half of 2010 to a peak of 14% in
the last half of 2012. After 2012, the proportion of women who
discontinued a bisphosphonate remained steady through the
end of 2014. The factors associated with discontinuation of alen-
dronate were mainly related to a worsening in the overall health
status, whereas the factors associated with restart of any osteo-
porotic medication after discontinuation of alendronate were
related to worsening bone health (eg, new osteoporotic
fracture).
Oral bisphosphonates, alendronate and risedronate, had a
smaller proportion of patients discontinue treatment than
patients treated with zoledronic acid. This noted difference
between zoledronic acid, an intravenous medication adminis-
tered yearly, and other oral bisphosphonates might be attribut-
able to zoledronic acid’s higher skeletal affinity, longer
retention, and/or issues with timely receipt.(20) We also found
that the increasing trend in discontinuation happened before
the 2016 ASBMR recommendation on drug holidays and could
partially reflect a response to a 2014 ASBMR report on atypical
femoral fractures and the FDA 2010 drug safety communica-
tion.(21,22) Indeed, in 2010, the FDA required that all bisphospho-
nate drug labels suggest a discontinuation after 3 to 5 years of
continuous use.
The prevalence of discontinuation in our study was similar to a
previous study showing that, with a 120-day gap definition, the
1-year discontinuation rate among alendronate users was
42.2%.(23) The small difference noted between that study and
ours might be explained by the slightly different definitions of
discontinuation. We defined discontinuation as a treatment
gap of >12 months compared with >4 months used in the study
by Lo and colleagues. Our study included long-term adherent
users (at least 3 years), whereas their analysis included patients
who were initiating alendronate only, allowing for withdrawal
related to early intolerance. Another similar analysis used a
60-day gap definition for discontinuation and showed that 58%
of patients initiating an osteoporosis medication discontinued
therapy by 12 months.(24) Defining discontinuation using shorter
periods may fail to reflect an intentional discontinuation but
Fig. 3. Temporal trends of bisphosphonate discontinuation in US Medicare women by calendar year.
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rather represent the effect of a concomitant relevant medical
event. For example, persons who develop acute medical illness
are more likely to discontinue nonessential medications leading
to a “sick-stopper” effect.(25) The careful consideration given to
our definitionsmake it more likely that our findings are indicative
of true drug holidays.
We determined that about 12% of those who discontinue a
bisphosphonate subsequently restarted therapy. This result is
lower than a previous study that reported 46% of patients who
discontinue medication subsequently reinitiate an osteoporosis
treatment, the majority within 6 months of discontinuation.(24)
One explanation for this disparate finding is that the larger pro-
portion could possibly be attributable to the shorter drug discon-
tinuation definition the other authors used. Indeed, this short-
term discontinuation of bisphosphonates might not be planned
and reflect only a temporary lack of adherence or drug
unavailability.
The factors associated with discontinuation of alendronate
were primarily associated with new medical diagnoses (eg, Alz-
heimer’s or other dementia), initiation of a medication suggest-
ing worsening of overall health status (eg, benzodiazepines,
vasodilators), or SNF care utilization. One of the possible explana-
tions of this finding is that women who have had a significant
worsening of health status (ie, new diagnosis or newmedication)
might consider the treatment of osteoporosis not essential,
futile, or even harmful. Interestingly, newly prescribed proton
pump inhibitors were one of the medications associated with
discontinuation. This might be reflective of real or perceived
gastrointestinal intolerance to alendronate. However, we have
included only women who have been highly adherent to long-
term bisphosphonate treatment, and such patients are less likely
to experience delayed gastrointestinal intolerance to alendro-
nate. The fact that patients who get sick with major medical con-
ditions often discontinue alendronate might not be justifiable or
desirable in many circumstances because those who have more
comorbidity may be the very patients in whom continued osteo-
porosis care is most necessary. However, the reasons behind the
decision to stop alendronate were unknown, given the nature of
this data source. We do not know if the decision of stopping an
osteoporosis medication was recommended by a bone specialist
or another health care provider with less expertise in osteoporo-
sis treatment or the patient alone. The factors associated with
restarting osteoporosis medication after alendronate discontinu-
ation were factors traditionally associated with worsening bone
health. Indeed, having a DXA scan was among the main factors
associated with restarting an osteoporosis medication. In addi-
tion, we found that, not surprisingly, patients who fracture are
more likely to restart a treatment than patients who do not frac-
ture. This result might be explained by the fact that patients who
fracture seek medical attention more intensely than patients
who do not fracture. Indeed, another factor strongly related to
restarting an osteoporosis medication as opposed to discontinu-
ation of alendronate was an office visit with an osteoporosis spe-
cialist (rheumatologist or endocrinologist). This difference could
be related to the concerns that osteoporosis specialists may have
about continued fracture risk or possibly in the onset of a new
Table 2. Baseline Characteristics of Patients Who Discontinued Bisphosphonates, Stratified by Those Who Restarted Any Osteoporosis
(OP) Therapy and Those Who Did Not













No. (%) 18,270 (89.3) 2185 (10.7) 2069 (86.6) 319 (13.4) 2702 (78.6) 736 (21.4)




79.2 (7.1) 78.0 (6.3) 79.5 (7.2) 77.7 (6.5) 79.5 (6.8) 77.7 (6.2)
65–69 (%) 1501 (8.2) 184 (8.4) 168 (8.1) 35 (11.0) 212 (7.8) 70 (9.5)
70–74 (%) 4509 (24.7) 633 (29.0) 522 (25.2) 90 (28.2) 583 (21.6) 205 (27.9)
75–79 (%) 4229 (23.1) 529 (24.2) 423 (20.4) 76 (23.8) 641 (23.7) 199 (27.0)
80–84 (%) 3913 (21.4) 507 (23.2) 434 (21.0) 70 (21.9) 621 (23.0) 164 (22.3)
85+ (%) 4118 (22.5) 332 (15.2) 522 (25.2) 48 (15.0) 645 (23.9) 98 (13.3)
Race (%) White 15,975 (87.4) 1897 (86.8) 1815 (87.7) 268 (84.0) 2587 (95.7) 708 (96.2)
Geographic region
on index date (%)
Midwest 5833 (31.9) 699 (32.0) 437 (21.1) 60 (18.8) 935 (34.6) 245 (33.3)
Northeast 3397 (18.6) 365 (16.7) 538 (26.0) 79 (24.8) 419 (15.5) 88 (12.0)
South 5881 (32.2) 722 (33.0) 731 (35.3) 124 (38.9) 1101 (40.7) 327 (44.4)
West 3159 (17.3) 399 (18.3) 363 (17.5) 56 (17.6) 247 (9.1) 76 (10.3)




Yes 2967 (16.2) 365 (16.7) 355 (17.2) 49 (15.4) 665 (24.6) 189 (25.7)
Ever CQ hip fracture
(%)
Yes 846 (4.6) 89 (4.1) 104 (5.0) 9 (2.8) 147 (5.4) 35 (4.8)
Ever CQ vertebral
fracture (%)
Yes 1331 (7.3) 175 (8.0) 144 (7.0) 26 (8.2) 388 (14.4) 113 (15.4)
Ever steroid (%) Yes 11,393 (62.4) 1394 (63.8) 1300 (62.8) 203 (63.6) 2223 (82.3) 609 (82.7)
Charlson score
category (%)
0 9028 (49.4) 1149 (52.6) 1030 (49.8) 155 (48.6) 1219 (45.1) 373 (50.7)
1–2 4749 (26.0) 567 (25.9) 512 (24.7) 98 (30.7) 789 (29.2) 205 (27.9)
3+ 4493 (24.6) 469 (21.5) 527 (25.5) 66 (20.7) 694 (25.7) 158 (21.5)
DXA = dual-energy X-ray absorptiometry; CQ = case qualifying.
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medical condition aggravating bone health and requiring a
rheumatologist or endocrinologist visit.
Some factors were associated both with discontinuation of
alendronate and restart of any osteoporosis medication. This
result might be secondary to different prescription indications.
For example, benzodiazepines and opioids might be used for
pain control in patients with a recent fracture; on the other hand,
the same drugs are prescribed for other medical reasons that
reflect the “sick stopper” effect and might introduce new per-
ceived contraindications to the osteoporosis medication.
Another at first sight unexpected result is the association
between diagnosis of osteoporosis and discontinuation of alen-
dronate. In our analysis, a diagnosis of osteoporosis represents
a new coding for osteoporosis and might be related to a mere
acknowledgment of the disease made by a physician during
the hazard period. Moreover, a new diagnosis of osteopenia
was more strongly associated with discontinuation than osteo-
porosis diagnosis, supporting the hypothesis that improved
BMD values were associated with discontinuation of
alendronate.
A key strength of this study is that our data are based on the
highly generalizable data from US women and their health care
providers who prescribe osteoporosis therapy. However, it has
some limitations common to administrative claims data. For
example, repeated refills of prescription claims for medications
do not indicate actual medication use with complete certainty.





1 and 2 Adjusted OR
n (%) n (%) (Wald 95% CI)
Factors associated with bone health
Case qualifying fragility fracture 441 (2.2) 400 (1.0) 1.2 (1.0, 1.4)
Osteopenia diagnosis 1499 (7.3) 1794 (4.4) 1.8 (1.7, 2.0)
Osteoporosis diagnosis 5510 (26.9) 7820 (19.1) 1.4 (1.3, 1.5)
Fall 744 (3.6) 986 (2.5) 1.0 (0.9, 1.1)
DXA scan 2884 (14.1) 3219 (7.9) 1.7 (1.6, 1.7)
Bone turnover markers 3 (0.0) 1 (0.0) 6.6 (0.7, 64.2)
At least 1 visit with an osteoporosis specialist (rheumatologist or
endocrinologist)
1328 (6.5) 2343 (5.7) 1.2 (1.0, 1.3)
Factors associated with overall health status
No. of unique days with at least 1 physician visit
0–1
6512 (31.8) 15,079 (36.9) ref
2–4 6605 (32.3) 13,694 (33.5) 1.0 (1.0, 1.1)
5 or more 7338 (35.9) 12,137 (29.7) 1.3 (1.2, 1.3)
Charlson comorbidity index
0
15,726 (76.9) 32,382 (79.2) ref
1 to 2 3507 (17.1) 6690 (16.4) 1.0 (0.9, 1.1)
3+ 1222 (6.0) 1838 (4.5) 1.1 (1.0, 1.3)
At least 1 ER visit 3694 (18.1) 4706 (11.5) 1.2 (1.1, 1.2)
At least 1 day hospitalized as inpatient 2538 (12.4) 2358 (5.8) 1.5 (1.3, 1.6)
Hospitalized stroke, MI, CHD, CVD event 97 (0.5) 130 (0.3) 0.7 (0.5, 1.0)
Any skilled nursing facility care 1163 (5.7) 791 (2.0) 1.9 (1.7, 2.2)
Alzheimer’s or other dementia 2176 (10.6) 2858 (7.0) 2.0 (1.8, 2.3)
Depression or anxiety 2251 (11.0) 3309 (8.1) 1.1 (1.0, 1.2)
Medications
Alpha blocker 1350 (6.6) 2456 (6.1) 1.6 (1.3, 1.9)
Anticholinergic antihistamine 284 (1.4) 538 (1.3) 0.9 (0.8, 1.1)
Antipsychotic 189 (0.9) 355 (0.9) 1.4 (0.8, 2.4)
Barbiturate 34 (0.2) 38 (0.1) 23.6 (3.1, 181.8)
Benzodiazepine 1168 (5.7) 1345 (3.3) 3.1 (2.7, 3.6)
Beta blocker 7871 (38.5) 15,238 (37.3) 1.3 (1.2, 1.4)
Muscle relaxant 712 (3.5) 1379 (3.4) 0.9 (0.8, 1.1)
Nonbenzodiazepine, benzodiazepine agonist 902 (4.4) 1801 (4.4) 0.9 (0.8, 1.1)
Opioid 4852 (23.7) 8823 (21.6) 1.1 (1.0, 1.1)
Oral glucocorticoids 1597 (7.8) 2949 (7.3) 1.2 (1.1, 1.3)
Proton pump inhibitor 4900 (24.0) 8684 (21.3) 1.8 (1.6, 1.9)
Selective serotonin reuptake inhibitor 3560 (17.4) 6613 (16.2) 1.5 (1.3, 1.7)
Tricyclic antidepressant 496 (2.4) 1055 (2.6) 0.7 (0.6, 1.0)
Vasodilator 992 (4.9) 1766 (4.3) 1.5 (1.3, 1.9)
OR = odds ratio; CI = confidence interval; DXA = dual-energy X-ray absorptiometry; ER = emergency room; MI = myocardial infarction; CHD = chronic
heart disease; CVD = cardiovascular disease.
Associations significant at p value <0.01 are in bold.
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We also could not assess the underlying reasons for treatment
discontinuation or restarting, and we did not have detailed infor-
mation on covariates that may influence care decisions, includ-
ing BMD result and biochemical markers of bone remodeling.
To attenuate confounders of starting and stopping therapy, we
designed a case-crossover study that controls for between-
patient confounding and within-person, time-invariant con-
founding. Nonetheless, since some residual confounding may
still be present in light of changes in health status, our results
should be interpreted cautiously.
In summary, we analyzed temporal trends of discontinuation
of bisphosphonates and sought to identify the factors associated
with the discontinuation and restart of alendronate. Bisphospho-
nate discontinuation increased substantially between 2010 and
2012 and then continued steadily through 2014. Among our
cohort of patients on long-term bisphosphonates, over a third
discontinued the medication for more than 12 months and,
among those, nearly 90% never restarted any osteoporosis med-
ication during the time frame of our study. The factors associated
with discontinuation of alendronate were predominately related
to a worsening in overall health, whereas the main factors asso-
ciated with restart of any osteoporosis medication were receipt
of a DXA scan and new fragility fractures. Our study depicts the
current trend in the discontinuation of bisphosphonates and
provides new insights about patient factors associated with dis-
continuation of alendronate and restart of any osteoporosis
medication at a population level. Further studies are needed to
better ascertain factors most strongly associated with









Factors associated with bone health
Case qualifying fragility fracture 183 (8.4) 86 (2.0) 2.8 (1.9, 4.0)
New osteopenia diagnosis 170 (7.8) 152 (3.5) 1.5 (1.1, 2.1)
New osteoporosis diagnosis 862 (39.5) 774 (17.7) 2.3 (1.9, 2.8)
Fall 135 (6.2) 124 (2.9) 1.4 (0.9, 2.0)
DXA scan 948 (43.4) 217 (5.0) 9.0 (7.6, 10.7)
Bone turnover markers 1 (0.1) 0 (0.0) NA
At least 1 visit with an osteoporosis specialist (rheumatologist or
endocrinologist)
273 (12.5) 367 (8.4) 1.4 (1.0, 1.9)
Factors associated with overall health status
No. of unique days with at least 1 physician visit0–1 630 (28.8) 1547 (35.4) ref
2–4 692 (31.7) 1386 (31.7) 0.9 (0.8, 1.1)
5 or more 863 (39.5) 1437 (32.9) 0.9 (0.8, 1.2)
Charlson comorbidity index0 1697 (77.7) 3502 (80.2) ref
1 to 2 363 (16.6) 675 (15.5) 0.9 (0.7, 1.1)
3+ 125 (5.7) 193 (4.4) 1.0 (0.7, 1.4)
At least 1 ER visit 457 (20.9) 582 (13.3) 1.3 (1.0, 1.6)
At least 1 day hospitalized as inpatient 276 (12.6) 342 (7.9) 0.8 (0.6, 1.0)
Hospitalized stroke, MI, CHD, CVD event 10 (0.5) 17 (0.4) 0.8 (0.3, 2.1)
Any skilled nursing facility care 152 (7.0) 133 (3.1) 1.9 (1.3, 2.8)
Alzheimer’s or other dementia 213 (9.8) 270 (6.2) 2.0 (1.4, 2.9)
Depression or anxiety 260 (11.9) 399 (9.1) 1.0 (0.8, 1.3)
Medications
Alpha blocker 166 (7.6) 304 (7.0) 1.6 (0.9, 2.9)
Anticholinergic antihistamine 24 (1.1) 39 (0.9) 1.7 (0.8, 3.7)
Antipsychotic 8 (0.4) 10 (0.3) 3.2 (0.4, 27.2)
Barbiturate 2 (0.1) 2 (0.1) NA
Benzodiazepine 220 (10.1) 346 (8.0) 2.7 (1.8, 3.9)
Beta blocker 790 (36.2) 1531 (35.0) 1.1 (0.8, 1.6)
Muscle relaxant 93 (4.3) 155 (3.6) 1.1 (0.7, 1.8)
Nonbenzodiazepine, benzodiazepine agonist 79 (3.6) 184 (4.3) 0.6 (0.3, 1.1)
Opioid 601 (27.5) 969 (22.2) 1.3 (1.1, 1.6)
Oral glucocorticoids 229 (10.5) 379 (8.7) 1.2 (0.9, 1.6)
Proton pump inhibitor 537 (24.6) 993 (22.7) 1.4 (1.0, 1.9)
Selective serotonin reuptake inhibitor 336 (15.4) 654 (15.0) 1.3 (0.8, 1.9)
Tricyclic antidepressant 39 (1.8) 77 (1.8) 1.3 (0.5, 3.0)
Vasodilator 97 (4.4) 198 (4.5) 0.9 (0.4, 1.7)
OR = odds ratio; CI = confidence interval; DXA = dual-energy X-ray absorptiometry; ER = emergency room; MI = myocardial infarction; CHD = chronic
heart disease; CVD = cardiovascular disease.
Associations significant at p value <0.01 are in bold.
1 Subgroup of the women in Table 3; treatment gap at least 365 days.
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discontinuation/restart of osteoporosis therapies and to design
future educational interventions aimed at avoiding unnecessary
or inappropriate bisphosphonate discontinuation and restarting.
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